Evidence map›Paper›PMID 42368561›Full record

ArticleActa pharmaceutica Sinica. B2026

VPS34 inhibition as a host-targeting anti-coronaviral strategy: Rational design of YBM with optimized pharmacokinetic parameters.

Chenchen Ge, Zihao Wang, Zhiwei Zhao, Xiaoyu Zhang, Xiaoyang Yu, Minghua Chen, Kai Liu, Lisen Lin, Dapeng Li, Ningyi Jin and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chenchen GeChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Zihao WangNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Zhiwei ZhaoCollege of Life Sciences, Shandong Normal University, Jinan 250014, China.
Xiaoyu ZhangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Xiaoyang YuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Minghua ChenChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Kai LiuChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Lisen LinChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Dapeng LiChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Ningyi JinChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Peifu JiaoNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Shiyong FanNational Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Chao ShangChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Xiao LiChangchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting host factors critical to the viral life cycle instead of direct viral enzyme inhibition represents a promising alternative strategy for developing broad-spectrum antivirals. Here, we identified VPS34, a key regulator of autophagosome-lysosome fusion and membrane trafficking, as a conserved host-dependency factor across coronaviruses.

Indexed as

Broad-spectrum anti-coronavirusHCoV-OC43Host-targeting antiviralsInhibitorsIn vivoPharmacokineticsSARS-CoV-2VPS34

Identifiers

PMID42368561
PMCPMC13304707

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.